

http://www.qualityforum.org

# Opioids and Behavioral Health Committee Web Meeting #1

Samuel Stolpe, PharmD, MPH Chris Dawson, MHA Katie Berryman, MPAP Karri Albanese

October 15, 2020

*This report is funded by the Centers for Medicare and Medicaid Services under contract HHSM-500-2017-00060I –75FCMC19F0007.* 

# Welcome



## Welcome

- The CenturyLink web platform will allow you to visually follow the presentation
- Please mute your lines when you are not speaking to minimize background noise.
- Please do not put the call on hold.
- You may submit questions to project staff via the CenturyLink web platform chat function.
- You may raise your hand using the CenturyLink web platform.

If you are experiencing technical issues, please contact the NQF project team at opioidbehavioralhealth@qualityforum.org



## **Project Staff**



Samuel Stolpe, PharmD, MPH Senior Director



Katie Berryman, MPAP, PMD Manager



Chris Dawson, MHA Manager



Karri Albanese Analyst



## Agenda

- Welcome and Introductions
- Overview of NQF
- Overview of Project
- Introduction to Environmental Scan
- Committee Discussion
- Opportunity for Public Comment
- Next Steps

# Attendance



## **Committee Members**

- Laura Bartolomei-Hill, LCSW-C (Co-Chair)
- Caroline Carney, MD, MSc, FAMP, CPHQ (Co-Chair)
- Jaclyn Brown
- Mary Ditri, DHA, MA, CHCC
- Carol Forster, MD
- Anita Gupta, DO, PharmD, MPP
- Barbara Hallisey, MSW, LCSW
- Lisa Hines, PharmD
- Brian Hurley, MD, MBA, DFASAM
- Margaret Jarvis, MD
- Sander Koyfman, MD
- Richard Logan, PharmD
- Perry Meadows, MD, JD, MBA

- Susan Merrill, MSW, LCSW
- Pete Nielsen, MA
- Rebecca Perez, MSN, RN, CCM
- Rhonda Robinson Beale, MD
- Tyler Sadwith
- Eric Schmidt, PhD
- Richard Shaw, LMSW, CASAC
- Sarah Shoemaker-Hunt, PhD, PharmD
- Eri Solomon
- Elizabeth Stanton, MD
- Steven Steinberg, MD
- Claire Wang, MD, ScD
- Sarah Wattenberg, MSW
- Jameela Yusuff, MD



## **Federal Liaisons**

- **Girma Alemu**, The Health Resources and Services Administration
- Ellen Blackwell, Centers for Medicare and Medicaid Services
- Jennifer Burden, United States Department of Veterans Affairs
- Laura Jacobus-Kantor, U.S. Department of Health & Human Services Office of the Assistant Secretary for Planning and Evaluation
- Joseph Liberto, United States Department of Veterans Affairs
- Wesley Sargent, The Centers for Disease Control and Prevention
- John Snyder, The Health Resources and Services Administration
- Shawn Terrell, The Administration for Community Living
- Jodie Trafton, United States Department of Veterans Affairs

# **Overview of National Quality** Forum



## **NQF** Mission

#### OUR MISSION

To be the trusted voice driving measurable health improvements

#### OUR VISION

Every person experiences high value care and optimal health outcomes

#### **OUR VALUES**

Collaboration • Leadership • Passion • Excellence • Integrity



## **Activities in Multiple Measurement Areas**

- Performance Measure Endorsement
  - 450+ NQF-endorsed measures across multiple clinical areas
  - 14 empaneled standing expert committees
- Measure Applications Partnership (MAP)
  - Provides recommendations to the Centers for Medicare and Medicaid Services (CMS) on selecting measures for 20 federal programs
- National Quality Partners
  - Convenes stakeholders around critical health and healthcare topics
  - Spurs action on patient safety, early elective deliveries, and other issues
- Measurement Science
  - Convenes private and public sector leaders to reach consensus on complex issues in healthcare performance measurement such as attribution, alignment, and sociodemographic status (SDS) adjustment

# **Overview of Opioids and Behavioral Health Committee**



## **U.S. Opioid Overdose Deaths**





## NQF Opioid TEP

- From 2019-2020, NQF convened the Opioid and Opioid Use Disorder Technical Expert Panel
- Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act of 2018
- Convened a Technical Expert Panel to recommend opioid and opioiduse disorder quality measures for possible use in value-based payment and reporting models under Medicare



## **Need for Opioid Quality Measures**

- Improving opioid-related care and health outcomes is a shared responsibility across medical care and social services
- Measurement is needed for:
  - Accountability
  - Incentivizing good care
  - Knowing where to direct resources
  - Establishing best practices



## **Opioid TEP Work**

- Environmental Scan and Gap Identification
  - Recommendations for revisions of existing quality measures
  - Need for development of new measures

#### Inclusion of quality measures in the 5 federal quality programs

- Merit-Based Incentive Payment System (MIPS)
- Alternative Payment Models (APMs)
- Shared Savings Program (SSP)
- Hospital Inpatient Quality Reporting (IQR) Program
- Hospital Value-Based Purchasing (VBP) Program



## **Opioid TEP Measurement Gaps & Priorities**

- Opioid Use Disorder (OUD) treatment with comorbidities
- Physical treatment such as cardiovascular etc. (i.e., regular screening for physical ailments in persons being treated for OUD)
- Mental health
- Other concomitant Substance Use Disorders



## **Opioids, Polysubstance Use, and Behavioral Health**

- Bidirectional relationship between Opioid Use Disorder and behavioral health problems
- Individuals with behavioral health problems are more likely to develop Opioid Use Disorder<sup>1-2</sup>
- Individuals with Opioid Use Disorder are more likely to develop behavioral health problems (e.g. depression, anxiety, suicidality, etc.)<sup>3</sup>
- 4th Wave of the Opioid Epidemic Polysubstance Use
- >60% of opioid related deaths involve additional substances<sup>4</sup>

1. Marel, C., M. Sunderland, K.L. Mills, et al (January 2019). Conditional probabilities of substance use disorders and associated risk factors: Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives, and opioids. *Drug and Alcohol Dependence*. Volume 194. Pp. 136-142. (https://www.sciencedirect.com/science/article/pii/S0376871618305313).

2. National Institute on Drug Abuse (NIDA). Comorbidity: Substance Use Disorders and Other Mental Illnesses. (https://www.drugabuse.gov/publications/drugfacts/comorbidity-substance-use-disorders-other-mental-illnesses).

3. Griesler, P.C., M.C. Hu, M.M. Wall, et al (September 2019) Medicl Use and Misuse of prescription Opioids in the U.S. Adult Population: 2016 – 2017. *American Journal of Public Health*. 109(9): 1258-1265. doi: 10.2105/AJPH.2019.305162

 4. Gladden, R.M., J. O'Donnells, C.L. Mattson, et al. (August 30, 2019). Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine – 25 States, July – December 2017 to January – June 2018. MMWR Morbidity and Mortality Weekly Report 2019;68:737–744 (https://www.cdc.gov/mmwr/volumes/68/wr/mm6834a2.htm?s\_cid=mm6834a2\_w)



### **Overview of Project**

- Up to 16 web meetings over a 24-month period
- Discuss the foundation of measurement framework that addresses polysubstance use involving synthetic or semi-synthetic opioids among individuals with co-occurring behavioral health conditions
- Guide recommendations to be highlighted in final report
- Provide input on project's components
- Provide expertise on measurement gaps and priorities
- Explore challenges and opportunities related to measuring opioid use as well as dependence prevention and treatment for individuals with behavioral health conditions



### **Overview of Project**

- Provide guidance on an environmental scan of the state of currently available measures, measure concepts and measurement gaps
- Develop measurement framework addressing polysubstance use involving synthetic or semi-synthetic opioids among individuals with cooccurring behavioral health conditions, considering specific short and long-term, innovative, actionable approaches to improve the current state of measurement in these areas along with disparities in these outcomes
- Focus on strategies to improve measurement for morbidity and mortality and details on how to use the measurement recommendations to support improving health outcomes



## **Role of Committee Members**

- Serve as experts working with NQF staff to achieve the goals of the project
- Review meeting materials and participate in all meetings
- Work towards meaningful consensus with your fellow Panel members
- Co-Chairs:
  - Facilitate Panel meetings and participate as Panel members
  - Keep the Panel on track to meet project goals without hindering critical discussion/input
  - Assist NQF in anticipating questions and identifying additional information that may be useful to the Panel



## **Role of Project Staff**

Work with the Committee to achieve project goals:

- Facilitate meetings and conference calls
- Ensure communication among all project participants
- Facilitate necessary communication and collaboration between different NQF projects and external stakeholders
- Respond to NQF member and public queries about the project
- Maintain documentation of project activities
- Draft and edit reports and project materials
- Publish environmental scan and final project report



## NQF Members and the Public at Large

NQF membership and the public can engage in the work by:

- Reviewing the draft reports and providing feedback to NQF and the Committee
- Participating in web meetings during opportunities for public comment

# **Environmental Scan**



## **Environmental Scan for Opioid Measures**

- Currently available all-payer measures or measure concepts that:
  - Address overdose and mortality resulting from polysubstance use involving synthetic or semi-synthetic opioids among individuals with co-occurring behavioral health conditions
  - Consider pertinent Social Determinants of Health to opioids
  - Measures or measure concepts related to non-medical levers or medical-non-medical partnership



## **Environmental Scan Data Bases**

- Centers for Medicare and Medicaid Services Measure Inventory Tool (CMIT)
- National Quality Forum Quality Positioning System (QPS)
- National Committee for Quality Assurance Healthcare Effectiveness
  Data and Information Set (HEDIS)
- Qualified Clinical Data Registries (QCDR)
- State Laws
- Medicaid Waiver Programs
- The Center for Medicare and Medicaid Innovation (CMMI) Models
- Literature Review

# **Committee Discussion**

# **Opportunity for Public Comment**



## **Next Steps**

Timeline	
Web Meeting #2	November 12, 2020
21-Day Comment Period (ES)	January 6 – 27, 2021
Web Meeting #3	February 11, 2021
Final Environmental Scan	March 15, 2021
Web Meeting #4	April 6, 2021
Web Meeting #5	May 5, 2021
Web Meeting #6	June 1, 2021
21-Day Comment Period (Report)	July 9 – 30, 2021
Web Meeting #7	August 18, 2021
Final Report	September 17, 2021



## **Project Information**

- Email: <u>opioidbehavioralhealth@qualityforum.org</u>
- Phone: (202) 783-1300
- Project Page: <u>http://www.qualityforum.org/Opioids and Behavioral Health Committee .aspx</u>
- SharePoint Page:
- https://share.qualityforum.org/

## THANK YOU.

#### NATIONAL QUALITY FORUM

http://www.qualityforum.org